Advertisement

Cognitive Assessment in Alzheimer’s Disease Clinical Trials

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1750)

Abstract

Many tests are available for the assessment of cognitive function. This chapter describes the common features and practical requirements of test administration, key considerations in the selection and interpretation of tests, and their application in Alzheimer’s disease drug development.

Key words

Neuropsychological assessment Cognitive assessment Methods Alzheimer’s disease Drug development 

References

  1. 1.
    Kipps CM, Hodges JR (2005) Cognitive assessment for clinicians. J Neurol Neurosurg Psychiatry 76(Suppl I):i22–i30CrossRefGoogle Scholar
  2. 2.
    Randolph C (1998) Repeatable battery for the assessment of neuropsychological status: manual. Pearson, BloomingtonGoogle Scholar
  3. 3.
    Stern RA, White T (2003) Neuropsychological assessment battery: administration, scoring, and interpretation manual. PAR, Inc., Lutz, FLGoogle Scholar
  4. 4.
    Benedict R, Brandt J (1997) Brief visuospatial memory test—revised (BVMT-R). PAR, Inc., Lutz, FLGoogle Scholar
  5. 5.
    Wechsler D (1997) Wechsler memory scale—third edition (WMS–III) administration and scoring manual. The Psychological Corporation, San Antonio, TXGoogle Scholar
  6. 6.
    Knight C, Alderman N, Burgess PW (2002) Development of a simplified version of the multiple errands test for use in hospital settings. Neuropsychol Rehabil 12(3):231–255CrossRefGoogle Scholar
  7. 7.
    Reitan RM, Wolfson D (1985) The Halstead–Reitan neuropsychological test battery: theory and clinical interpretation. Neuropsychological Press, Tucson, AZGoogle Scholar
  8. 8.
    Wechsler D (2008) Wechsler adult intelligence scale—fourth edition (WAIS-IV) administration and scoring manual. The Psychological Corporation, San Antonio, TXGoogle Scholar
  9. 9.
    Folstein M, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefGoogle Scholar
  10. 10.
    Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H (2010) Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 11:118CrossRefGoogle Scholar
  11. 11.
    Beglinger LJ, Gaydos B, Tangphao-Daniels O et al (2005) Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 20(4):517–529CrossRefGoogle Scholar
  12. 12.
    McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34(7):939–944CrossRefGoogle Scholar
  13. 13.
    Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746CrossRefGoogle Scholar
  14. 14.
    Simard M (1998) The mini-mental state examination: strengths and weaknesses of a clinical instrument. Can Alzheimer Dis Rev 12:10–12Google Scholar
  15. 15.
    Donohue MC, Sperling RA, Salmon DP et al (2014) The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71(8):961–970CrossRefGoogle Scholar
  16. 16.
    Fray PJ, Robbins TW, Sahakian BJ (1996) Neuropsychiatric applications of CANTAB. Int J Geriatr Psychiatry 11:329–336CrossRefGoogle Scholar
  17. 17.
    Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64(9):1323–1329CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Faculty of Medicine, Neuroepidemiology and Ageing Research UnitSchool of Public Health, The Imperial College of Science Technology and MedicineLondonUK

Personalised recommendations